Igm Biosciences (IGMS) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Igm Biosciences in October 2026.
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
Igm Biosciences (IGMS) Stock Forecast
Analyst price target, next 12 months
$6.25
+239.7% vs today's $1.84
Price range over the last 12 months
Close to its 12-month low
Analysts covering Igm Biosciences have a consensus 12-month target of $6.25, above the current price of $1.84.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 17 Jan 2025.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding IGM Biosciences stock with a target price of $5.13, indicating possible growth.
Financial Health
IGM Biosciences has limited revenue and cash flow, indicating challenges in financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
